Clinical Trials in New York State

Showing 13781-13800 of 17,167 trials

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

NCT01087944

This randomized, cross-over, open label study will compare the tolerability and handling of application of peginterferon alfa-2a \[Pegasys\] by autoinjector versus pre-filled syringe in patients with chronic hepatitis C, either on treatment with peginterferon alfa-2a for at least 12 weeks or treatment-naïve for peginterferon alfa-2a. Patients will be randomized to self-injection of 180mcg peginterferon alfa-2a once a week using either an autoinjector or a prefilled syringe for 3 weeks, then switch to use the other method of injection for another 3 weeks. Anticipated time on study treatment is 6 weeks. Target sample size is \<100 patients.

Hepatitis C, Chronic

Hoffmann-La Roche60 participantsStarted Mar 2010

Los Angeles, California, United States • Bradenton, Florida, United States • Orlando, Florida, United States +9 more locations

COMPLETED86 miles

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265

A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies

Pulmonary Arterial Hypertension

United Therapeutics1,333 participantsStarted Dec 2010

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +85 more locations

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

Find Trials by Condition in New York State

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Blood and Marrow Transplant Clinical Research Network

Imatinib (QTI571) in Pulmonary Arterial Hypertension

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

AqueSys Microfistula Implant in Refractory Glaucoma

Atacicept in Subjects With Optic Neuritis

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

Relapse Prevention Study in Newly Abstinent Smokers

Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU

Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

A Novel Diet-Phenotype Interaction Affecting Body Weight

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis